The antimicrobial resistance surveillance market, valued at USD 5.90 billion in 2023, is projected to reach USD 9.50 billion by 2032, advancing at a CAGR of 5.47% during 2024–2032. The expanding threat of antimicrobial resistance (AMR) continues to reshape global healthcare priorities, pushing governments, hospitals, laboratories, and research institutes to strengthen early detection and global data-sharing networks. As resistance increases across bacterial and fungal pathogens, the antimicrobial resistance surveillance market has evolved into a critical support system for evidence-based decisions, enabling healthcare leaders to develop timely interventions that safeguard public health.
Antimicrobial resistance is now recognized as one of the world’s most pressing health crises. AMR currently contributes to an estimated 700,000 deaths each year, and data shows the true burden may be significantly higher. The year 2019 alone saw approximately 4.95 million deaths associated with drug-resistant infections, and projections indicate that AMR could claim up to 10 million lives annually by 2050 if left unaddressed. The economic implications are equally alarming, with estimates warning of global GDP losses between 1.1% and 3.8% by mid-century. Against this backdrop, surveillance plays a pivotal role in preventing a public health and economic catastrophe.
A powerful example is the ATLAS platform, which expanded in 2020 to include antifungal surveillance. With data from more than 15,500 fungal isolates from 40 countries, ATLAS is one of the most comprehensive global systems for understanding resistance trends. Annual updates ensure healthcare and regulatory stakeholders have real-world data, allowing them to optimize treatment guidelines, refine stewardship programs, and prevent the spread of highly resistant pathogens. Such surveillance ecosystems form the backbone of the antimicrobial resistance surveillance market, which increasingly relies on integrated diagnostics, artificial intelligence, and centralized reporting software.
The WHO’s Global Antimicrobial Resistance and Use Surveillance System (GLASS) remains another cornerstone of global AMR monitoring. Since its launch in 2015, GLASS has grown to include antibiotic consumption tracking and antifungal resistance surveillance, reflecting a holistic “One Health” approach that links human, animal, and environmental health. With participation from more than 127 countries by 2022, GLASS provides policymakers with critical insight into resistance patterns, enabling more effective infection control plans and international collaboration.
On a national level, the United States’ NARMS program showcases how surveillance improves regulatory and clinical outcomes. Established in 1996, NARMS represents a coordinated effort among the CDC, FDA, USDA, and state public health departments. Its surveillance data directly informs FDA regulatory decisions, ensuring antibiotics used in human and veterinary medicine remain effective for future generations. NARMS exemplifies how localized programs contribute to the broader antimicrobial resistance surveillance market through actionable data and strong governance.
Key Drivers & Restraints
Growth in the antimicrobial resistance surveillance market is primarily fueled by the rising global burden of AMR, expansion of infectious disease diagnostic technologies, and increasing government investment in national surveillance programs. The rapid spread of multidrug-resistant organisms across hospitals, communities, and agricultural settings has heightened the need for accurate, real-time data. Innovations in rapid diagnostic kits, automated systems, surveillance software, and cloud-based data integration are accelerating market adoption. Meanwhile, a major restraint is the inconsistent quality of data collection across low- and middle-income countries, along with limited infrastructure and workforce shortages that hinder uniform global surveillance.
Key Opportunities & Challenges
The antimicrobial resistance surveillance market presents strong opportunities for improved genomic sequencing, AI-driven data analytics, and cross-border collaborative networks. The rising use of whole genome sequencing (WGS) is enabling detailed tracking of resistance genes, while AI algorithms help predict emerging threats before they become widespread. Partnerships between public health bodies, biotech companies, and digital health providers are expected to shape the next decade of market growth. However, data standardization, high implementation costs, and resistance evolution occurring faster than surveillance systems can adapt remain significant challenges. Harmonizing reporting frameworks across regions is essential for long-term progress.
Key Segments
The antimicrobial resistance surveillance market is segmented by solution, application, and end user. Solutions include diagnostic kits, diagnostic systems, surveillance software, and services—each playing a distinct role in strengthening surveillance capabilities. Applications span clinical diagnostics, public health surveillance, and specialized research uses. Hospitals and clinics remain the largest end users due to the high incidence of drug-resistant infections in healthcare settings, followed by research and academic institutes, which increasingly rely on genomic and predictive tools to study AMR dynamics.
Regional Analysis
North America holds a dominant position in the antimicrobial resistance surveillance market due to advanced healthcare infrastructure, strong federal programs like NARMS, and the presence of major biotechnology and diagnostic companies. Europe follows, supported by extensive national AMR strategies and regional collaborations. Asia Pacific is anticipated to experience the fastest growth as countries like China, India, Japan, and South Korea increase investment in public health surveillance and infectious disease control systems. Meanwhile, the Middle East & Africa and Latin America are upgrading laboratory networks and integrating new surveillance technologies, although challenges such as resource constraints and inconsistent reporting still persist.
Company Profiles
Major companies operating in the antimicrobial resistance surveillance market include Danaher, Bioanalyse, Luminex Corporation, Alifax S.r.l., Thermo Fisher Scientific, Wolters Kluwer N.V., Lumed, BioSpace, Roche Diagnostics, OpGen, Inc., Cepheid, Abbott Laboratories, Accelerate Diagnostics, Inc., Qiagen, Liofilchem S.r.l., Bio-Rad, Merck KGaA, Becton, Dickinson and Company, Bruker, Biomerieux, and others. These companies are expanding product portfolios, integrating automation, and enhancing digital connectivity to support real-time AMR monitoring.
Future Outlook
The future of the antimicrobial resistance surveillance market lies in stronger digital ecosystems, precision diagnostics, and global cooperation. Countries are expected to adopt more advanced technologies such as cloud-based reporting dashboards, genomic sequencing tools, and AI-powered predictive platforms. Public–private partnerships will play an essential role as the world intensifies efforts to stay ahead of rapidly evolving pathogens. With AMR increasing across healthcare and community settings, the demand for comprehensive surveillance solutions will continue to rise, shaping the next era of global health preparedness.
Conclusion
The antimicrobial resistance surveillance market is on a steady upward path as nations confront one of the most significant health threats of the modern era. Continuous surveillance, supported by advanced diagnostics and data analytics, remains essential to safeguard human and economic stability worldwide. As resistance accelerates, there is an urgent need for coordinated global strategies, innovation, and investment to ensure the world remains equipped to respond effectively.
Melissa Williams 
Alex Hamilton